# US 2016/0250153 A1 · Novel methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250153 A1
- Document ID: US20160250153A1
- Status: Published application
- Kind: A1
- Application number: 15/153,807
- Filed: 2016-05-13
- Published: 2016-09-01
- Earliest claimed: 2012-01-13
- Assignees: Xspray Microparticles AB
- Applicants: Xspray Microparticles AB
- Inventors: Magnus BRISANDER; Mustafa DEMIRBÜKER; Gérald JESSON; Martin MALMSTEN; Helene DÉRAND
- Web page: https://patentgrep.com/patent/US20160250153A1

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/5192: {Processes}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the field of methods for providing components of pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to methods for providing stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions.

## Claims

### Claim 1

A method of producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, comprising
a) providing a first pressurized stream of said protein kinase inhibitor dissolved in a solvent;
b) providing a second pressurized stream of antisolvent;
wherein said at least one polymeric stabilizing and matrix-forming component is present in either said first or second stream; and
c) mixing said first and second streams, and spraying the mixed stream at the outlet of a nozzle, whereby said hybrid nanoparticles are formed; followed by collecting said hybrid nanoparticles.

### Claim 2 (depends on 1)

The method of claim 1, wherein said polymeric stabilizing and matrix-forming component is present in said solvent.

### Claim 3 (depends on 1)

The method of claim 1, wherein said polymeric stabilizing and matrix-forming component is present in said antisolvent.

### Claim 4 (depends on 1)

The method according to claim 1, wherein at least one of said fluid streams is a supercritical fluid stream, preferably a super- or subcritical CO2 fluid stream.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said stream of antisolvent is a super- or subcritical CO2 fluid stream.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said stream of solvent is a super- or subcritical CO2 fluid stream.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said at least one polymeric stabilizing and matrix-forming component is present in a super- or subcritical CO2 fluid stream.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said first stream or said second stream is comprised of a super- or subcritical CO2 fluid stream is provided at a temperature of about 25° C. or lower, at a pressure of from about 100 to about 150 bar.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said at least one polymeric stabilizing and matrix-forming component is selected from methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinylpyrrolidone, polyvinyl acetate phthalate, copolyvidone, crospovidon, methacrylic acid and ethylacrylate copolymer, methacrylate acid and methyl methacrylate copolymer, polyethylene glycol, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, DL lactide/glycolide copolymer, poly DL-lactide, cellulose acetate phthalate, carbomer homopolymer Type A, carbomer homopolymer Type B, aminoalkyl methacrylate copolymers and polaxamers.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said at least one polymeric stabilizing and matrix-forming component is selected from hydroxypropyl methylcellulose phthalate, hydroxypropyl cellulose, copolyvidone, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate and polyvinylpyrrolidone.

### Claim 11 (depends on 1)

The method according to claim 1, wherein a solubilizer is added to the hybrid nanoparticles obtained in step c.

### Claim 12 (depends on 11)

The method of claim 11, wherein said solubilizer is selected from polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, d-α-tocopherol acid polyethylene glycol 1000 succinate and a hydrogenated castor oil.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said hybrid nanoparticles comprising said protein kinase inhibitor provide an increased dissolution rate, compared to the dissolution rate of said protein kinase inhibitor in raw, crystalline form.

### Claim 14 (depends on 13)

The method of claim 13, wherein said dissolution rate is measured by a flow through cell system.

### Claim 15 (depends on 13)

The method of claim 13, claim 13, wherein said dissolution rate is measured within the initial 0 to 10 minutes of dissolution.

### Claim 16 (depends on 13)

The method according to claim 13, wherein said increased dissolution rate is measured in a solution as a dissolution rate ratio of said hybrid nanoparticles comprising said protein kinase inhibitor and said protein kinase inhibitor in raw, crystalline form.

### Claim 17 (depends on 16)

The method of claim 16, wherein said ratio is from about 1.5:1 to about 500:1.

### Claim 18 (depends on 13)

The method according to claim 13, wherein said dissolution rate is measured in a solution with a gastric pH.

### Claim 19 (depends on 13)

The method according to claim 13, wherein said dissolution rate is measured in a solution with an intestinal pH.

### Claim 20 (depends on 1)

The method according to claim 1, which produces hybrid nanoparticles that provide a solubility increase of said protein kinase inhibitor in a solution, said increase measured as the area under the curve (AUC) during about from 40 minutes to about 90 minutes, in said solution as compared with the AUC of said protein kinase inhibitor in raw, crystalline form.

### Claim 21 (depends on 20)

The method of claim 20, wherein said increase is from about 2:1 to about 10 000:1, wherein 1 represents the AUC of said protein kinase inhibitor in raw, crystalline form.

### Claim 22 (depends on 20)

The method of claim 20, wherein said increase is measured in a solution with gastric pH.

### Claim 23 (depends on 20)

The method according to claim 20, wherein said increase is measured in a solution with an intestinal pH.

### Claim 24 (depends on 1)

The method according to claim 1, wherein said amorphous hybrid nanoparticles are characterized by providing an amorphous powder X-ray diffraction pattern.

### Claim 25 (depends on 1)

The method according to claim 1, wherein the dissolution rate of said stable, amorphous hybrid nanoparticles remain stable to at least about 90%, after 9 months of storage or more, at room temperature.

### Claim 26 (depends on 1)

The method according to claim 1, wherein said protein kinase inhibitor is a tyrosine kinase inhibitor selected from the group consisting of lapatinib, pazopanib, nilotinib, erlotinib, dasatinib, gefitinib, sorafenib, crizotinib, axitinib, vemurafenib salts thereof, hydrates thereof, solvates thereof, and combinations thereof.

### Claim 27 (depends on 1)

The method according to claim 1, wherein said hybrid nanoparticles have an average particle diameter size of less than about 1000 nm.

### Claim 28 (depends on 1)

The method according to claim 1, wherein said hybrid nanoparticles have an average diameter size is less than about 500 nm.

### Claim 29 (depends on 1)

The method according to claim 1, wherein said solvent is an organic solvent selected from DMSO and trifluoroethanol, or a mixture thereof.

### Claim 30 (depends on 1)

The method according to claim 1, wherein said hybrid nanoparticles further comprise a solubilizer.

### Claim 31 (depends on 30)

The method of claim 30, wherein said solubilizer is polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol copolymer, d-α-tocopherol acid polyethylene glycol 1000 succinate or a hydrogenated castor oil.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method according to claim 1, further comprising
formulating said hybrid nanoparticles obtained from step (c) as a pharmaceutical composition,
wherein said pharmaceutical composition optionally further comprises a pharmaceutically acceptable excipient.
